Drug Inhibition in HER2-Mutant Colorectal Cancer Cell Lines as a Basis for Novel Treatments

Date Submitted

Spring 4-17-2015

Research Mentor and Department

Ron Bose, M.D., Ph.D.




Understanding the molecular mechanisms of drug resistance is a prerequisite to more effective cancer treatments. Therapeutically pinpointing clinically-relevant genetic alterations represents a promising avenue for overcoming drug resistance and improving the efficacy of current treatments. Amplification of HER2, an epidermal growth factor receptor (EGFR) family receptor tyrosine kinase, has been extensively studied because of its role in key cell proliferation pathways. However, somatic mutations in HER2 are only recently being explored as clinically-relevant.


This poster is not available at the author's request.

This document is currently not available here.